Combination treatment for pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether combining two medications, nerandomilast and mycophenolate, helps people with different types of pulmonary fibrosis (lung scarring). It aims to see if this combination is safe and works well for various subtypes other than IPF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of pulmonary fibrosis (lung scarring) that is not IPF (idiopathic pulmonary fibrosis), with at least 10% scarring seen on a CT scan within the past year.
- Your doctor thinks you could benefit from nerandomilast.
- You have been taking a stable dose of mycophenolate for at least 3 months, at a daily dose of 1500 mg or more (or 1080 mg of the sodium form).
- Your lung condition has been stable for the past 6 weeks, with no urgent hospital visits or need for extra steroids.
- Your lung function test results (FVC and DLCO) must be above certain thresholds (FVC at least 45% and DLCO at least 25% of predicted values).
- You have not taken certain other medications recently, including prednisone (over 10 mg/day for more than 2 weeks), azathioprine, cyclophosphamide, rituximab, tocilizumab, pirfenidone, or nintedanib, within the specified time frames.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study looks at how patients and doctors decide on treatment for pulmonary fibrosis. It aims to understand the impact of side effects from antifibrotic medicines on treatment choices.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.